newsfilter
← Latest News
GlobeNewswire·

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million